Novavax has announced positive results of their phase 3 PREVENT-19 clinical trial (NCT04511802) evaluating the company’s recombinant nanoparticle protein-based COVID-19 vaccine, NVX-CoV2373.1
The vaccine both achieved the primary effectiveness endpoint—neutralizing antibody responses noninfoerior to those seen in young adult participants of PREVENT-19—and demonstrated an 80% overall efficacy when the Delta SARS-CoV-2 variant was predominant.
The pediatric expansion of the PREVENT-19 trial enrolled 2247 adolescents aged 12 to 17 years across 73 sites in the United States. Trial investigators emphasized the importance of ensuring “well balanced racial and ethnic representation among participants.”
